Novartis: Anemia trials
The registry lists 19 Anemia studies with Novartis as lead sponsor. 1 are open to participants now and 11 have results posted.
Phase 1 2Phase 2 3Phase 3 12No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsRecruitingNCT06934967Phase 3
- Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyCompletedNCT04820530Phase 3Results posted
- Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentCompletedNCT04558918Phase 3Results posted
- Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.CompletedNCT02966353Phase 2Results posted
- Extended Evaluation of Deferasirox Film-coated Tablet (FCT) FormulationCompletedNCT02720536Phase 3Results posted
- Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin AlfaCompletedNCT01693029Phase 3Results posted
- LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)TerminatedNCT01034657Phase 2Results posted
- Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer PatientsCompletedNCT00711958Phase 3Results posted
- Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis PatientsTerminatedNCT00701714Phase 3Results posted
- Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis PatientsCompletedNCT00666835Phase 3Results posted
- Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia PatientsCompletedNCT00303329Phase 2Results posted
- Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3Results posted
- Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT04747613Phase 3
- A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency AnemiaCompletedNCT03399084Phase 1
- A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis PatientsCompletedNCT02570854Phase 1
- MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5CompletedNCT01121237
- Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)WithdrawnNCT00869856Phase 3
- ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With DeferasiroxCompletedNCT00466063
- A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadCompletedNCT00171821Phase 3